- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04710589
CTV Exploration of 3D-PT Assisted CT-guided I-125 Seeds Implantation for Recurrent Rectal Cancer
January 13, 2021 updated by: Peking University Third Hospital
Clinical Target Volume Exploration of 3D Printing Personalized Template Assisted CT-guided Radioactive Iodine-125 Seeds Implantation as a Salvage Treatment for Recurrent Rectal Cancer Patients After Operation and Radiotherapy
This study is to explore the progression-free survival time (PFS) , overall survival time (OS), quality of life and side effects between two different clinical target volumes in the treatment of 3D printing template-assisted CT-guided radioactive iodine-125 seeds implantation for recurrent rectal cancer after surgery and radiotherapy and investigate the clinical and dosimetric prognosis factors for outcomes.
Study Overview
Status
Recruiting
Intervention / Treatment
Detailed Description
From June 2019 to December 2020 in each participating center, patients with recurrent rectal cancer after surgery and radiotherapy will be included in the study if they meet the inclusion criteria and do not meet the exclusion criteria.
According to the clinical conditions of the patients, they will be assigned to groups A or B according to the doctor's recommendations and their own wishes.
GTV of both groups are visible tumors.
The CTV of group A is expanded by 3mm on the basis of GTV, and the CTV of group B is expanded by 6mm.
Both groups A and B received prescription dose: 95% GTV (120-160) Gy, 95% CTV (90-120) Gy.
The activities of 125I seeds will be 0.4mCi-0.7mCi.
All patients will receive 3D printed template-assisted 125I seeds implantation and be followed up.
The differences in local progression-free survival time, overall survival time, change of quality of life, and side effects between different groups will be prospectively analyzed.
Study Type
Observational
Enrollment (Anticipated)
60
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Xuemin Li, Dr
- Phone Number: +86-15201304917
- Email: lixueminrz@163.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100191
- Recruiting
- Peking Unnversity Third Hospital
-
Contact:
- Xuemin Li, Dr
- Phone Number: +86-15201304917
- Email: lixueminrz@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Recurrent rectal cancer after surgery and radiotherapy who will receive 3D-PT Assisted CT-guided I-125 Seeds Implantation
Description
Inclusion Criteria:
- KPS score above 60;
- Age from 18 to 80 years old;
- Rectal cancer by histological diagnosis, recurrence after surgery and radiotherapy;
- The diameter of the lesion ≤ 5cm;
- The tumor has not invaded the intestines or bladder;
- The estimated survival time is more than 3 months;
- The percutaneous puncture path is feasible and the preoperative plan can meet the prescription dose;
- Blood routine, liver, kidney and other major organ functions: WBC is normal, PLT≥100×109/L, HGB≥100g/L; urea nitrogen, creatinine≤1.25×upper limit of normal (UNL), ALT (SGPT) and AST (SGOT) ≤2.5×UNL; ECG is basically normal;
- Recurrence in pelvic region after surgery and radiotherapy for various reasons; or oligo-metastatic lesions less than 3, which are stable with treatment. Except for rectal incision stump and recurrence at the anastomosis.
Exclusion Criteria:
- Major organ failure, decompensated heart and lung failure such as congestive heart failure, coronary heart disease with clinical symptoms, and arrhythmia that cannot be controlled by drugs;
- Patients with other serious uncontrollable medical diseases;
- Severe coagulation dysfunction;
- With serious infection or ulcer at the puncture site;
- Pregnancy, breastfeeding women, children and mental patients;
- Patients with severe diabetes;
- Cases that invade large blood vessels and vital organs, which may cause hemorrhage and severe organ dysfunction;
- Those who have participated in clinical trials of other drugs or medical devices before being selected but have not reached the time limit of the main research endpoint or have completed clinical trials of other drugs or medical devices for less than 4 weeks;
- Poor compliance and unable to complete the course of treatment;
- Other reasons the researchers think it is inappropriate to participate in this clinical trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
CTV 3mm
CTV is expanded by 3mm on the basis of GTV.
|
|
CTV 6mm
CTV is expanded by 6mm on the basis of GTV.
|
According to the clinical conditions of the patients, they will be assigned to two groups based on the doctor's recommendations and their own wishes
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression free survival time (PFS)
Time Frame: 3 years
|
The time from 125I radioactive seeds implantation to local failure or death.
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival time (OS)
Time Frame: 3 years
|
The time from 125I radioactive seeds implantation to death due to any cause.
|
3 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Karnosky Score
Time Frame: 3 years
|
This is a functional status score, which is one of the methods to evaluate the quality of life.
The range is from 0-100 points.
The higher the score, the better the functional status and the higher the quality of life are.
|
3 years
|
Visual Analogue Score
Time Frame: 3 years
|
This is a pain score ,which is one of the evaluation indicators of quality of life.
The range is 0-10 points.
The higher the score, the higher the pain and the worse the quality of life are.
|
3 years
|
Side effects
Time Frame: 3 years
|
Difined and classified by RTOG
|
3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
January 1, 2020
Primary Completion (ANTICIPATED)
December 31, 2022
Study Completion (ANTICIPATED)
December 31, 2023
Study Registration Dates
First Submitted
December 30, 2020
First Submitted That Met QC Criteria
January 13, 2021
First Posted (ACTUAL)
January 14, 2021
Study Record Updates
Last Update Posted (ACTUAL)
January 14, 2021
Last Update Submitted That Met QC Criteria
January 13, 2021
Last Verified
January 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CTV of 125I for rectal cancer
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Rectal Cancer
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage IV Colon Cancer | Stage IV Rectal Cancer | Recurrent Colon Cancer | Recurrent Rectal CancerUnited States
-
National Cancer Institute (NCI)CompletedStage IV Colon Cancer | Stage IV Rectal Cancer | Recurrent Colon Cancer | Recurrent Rectal CancerUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer | Stage IVB Colon Cancer | Stage IVB Rectal CancerUnited States
-
Vanderbilt-Ingram Cancer CenterTerminatedRecurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer | Stage IVB Colon Cancer | Stage IVB Rectal CancerUnited States
-
National Cancer Institute (NCI)CompletedStage IV Colon Cancer | Stage IV Rectal Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage III Colon Cancer | Stage III Rectal CancerUnited States
-
National Cancer Institute (NCI)CompletedStage IV Colon Cancer | Stage IV Rectal Cancer | Recurrent Colon Cancer | Recurrent Rectal CancerCanada
-
National Cancer Institute (NCI)CompletedStage IV Colon Cancer | Stage IV Rectal Cancer | Recurrent Colon Cancer | Recurrent Rectal CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI); Array BioPharmaCompletedRecurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer | Stage IVB Colon Cancer | Stage IVB Rectal CancerUnited States
-
National Cancer Institute (NCI)Eastern Cooperative Oncology Group; NCIC Clinical Trials Group; Cancer and Leukemia... and other collaboratorsTerminatedRecurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer | Stage IVB Colon Cancer | Stage IVB Rectal CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)WithdrawnRecurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer | Stage IVB Colon Cancer | Stage IVB Rectal CancerUnited States
Clinical Trials on CTV
-
Zhongshan People's Hospital, Guangdong, ChinaRecruitingNasopharyngeal Carcinoma ,Xerostomia,RadiotherapyChina
-
Sun Yat-sen UniversityCompletedTarget Volume Delineation | Early-stage Nasopharyngeal Carcinoma | Intensity Modulated Radiation TherapyChina
-
Chongqing University Cancer HospitalRecruitingNasopharyngeal Carcinoma by AJCC V8 StageChina
-
Manchester University NHS Foundation TrustManchester Metropolitan UniversityRecruiting
-
Guizhou Medical UniversityUnknownRadiotherapy | Nonsmall Cell Lung Cancer, Stage IVChina
-
Hubei Cancer HospitalRecruitingNon Small Cell Lung Cancer | Radiotherapy | Immunotherapy | Locally AdvancedChina
-
Hubei Cancer HospitalRecruitingRadiotherapy | Immunotherapy | Advanced Non-Small Cell Squamous Lung CancerChina
-
Jianguo SunCompletedStage III Non-small-cell Lung Cancer
-
Osel, Inc.University of California, San Francisco; Aurum Institute; Harvard University; University... and other collaboratorsCompletedHIV Infections | Bacterial VaginosisSouth Africa
-
University of WashingtonNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed